13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001590144
Total reported value
$37.0M
$37.0M
8 檔
38.9%
The Q3 2025 SEC filing reveals that Pura Vida Investments, LLC held a total portfolio value of $37.0M, covering 8 public equity positions.
In Q3 2025, Pura Vida Investments, LLC adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 1 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including BBNX, IMDX, CAI) accounted for 38.9% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBNX | Beta Bionics Inc | Stock-Other | 34.05% | -7.03% | +11150.00% | |
| 2 | IMDX | Insight Molecular Diagnostic | Stock-Other | 19.16% | -13.15% | +4964.89% | |
| 3 | CAI | Caris Life Sciences Inc | Stock-Other | 16.58% | -9.58% | +99.87% | |
| 4 | ✓ | Establishment Labs Holdings In | Stock-Other | 11.24% | -6.73% | -49.97% | |
| 5 | NSPR | Inspiremd Inc | Stock-Other | 6.62% | -4.09% | — | |
| 6 | OM | Outset Medical Inc | Stock-Other | 6.09% | -1.18% | -98.83% | |
| 7 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 3.82% | -1.53% | -72.23% | |
| 8 | NTRA | Natera Inc | Stock-Healthcare | 2.45% | -2.26% | -98.98% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MGX | Metagenomi Therapeutics Inc | +1.2% | -72.23% | Unchanged |
| 2 | OM | Outset Medical Inc | +0.4% | -98.83% | Unchanged |
| 3 | NTRA | Natera Inc | -0.1% | -98.98% | Unchanged |
| 4 | IMDX | Insight Molecular Diagnostic | -2% | +4964.89% | Unchanged |
| 5 | ✓ | Establishment Labs Holdings In | -2.2% | -49.97% | Unchanged |
| 6 | NSPR | Inspiremd Inc | -2.2% | — | Unchanged |
| 7 | BBNX | Beta Bionics Inc | -4.3% | +11150.00% | Trim |
| 8 | CAI | Caris Life Sciences Inc | — | NEW | New buy |
| 9 | KMTS | Kestra Medical Technologies, Ltd. | — | EXIT | Sold out |
According to official SEC Form 13F filings, Pura Vida Investments, LLC reported a total U.S. public equity portfolio value of $37.0M across 8 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CAI
市值: $2.7M
Top Position Liquidated / Trimmed
KMTS
前期市值: $996.8K
During Q3 2025, Pura Vida Investments, LLC's top holdings by market value included BBNX (34.0%)、IMDX (19.2%)、CAI (16.6%). The largest single position, BBNX, represented 34.0% of total portfolio value.
In Q3 2025, Pura Vida Investments, LLC made 3 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.